The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Open accessAbstract
The rates and routes of lethal systemic spread in breast cancer are poorly understood owing to a lack of molecularly characterized patient cohorts with long-term, detailed follow-up data. Long-term follow-up is especially important for those with oestrogen-receptor (ER)-positive breast cancers, which can recur up to two decades after initial diagnosis1–6. It is therefore essential to identify patients who have a high risk of late relapse7–9. Here we present a statistical framework that models distinct disease stages (locoregional recurrence, distant recurrence, breast-cancer-related death and death from other causes) and competing risks of mortality from breast cancer, while yielding individual risk-of-recurrence predictions. We apply this model to 3,240 patients with breast cancer, including 1,980 for whom molecular data are available, and delineate spatiotemporal patterns of relapse across different categories of molecular information (namely immunohistochemical subtypes; PAM50 subtypes, which are based on gene-expression patterns10,11; and integrative or IntClust subtypes, which are based on patterns of genomic copy-number alterations and gene expression12,13). We identify four late-recurring integrative subtypes, comprising about one quarter (26%) of tumours that are both positive for ER and negative for human epidermal growth factor receptor 2, each with characteristic tumour-driving alterations in genomic copy number and a high risk of recurrence (mean 47–62%) up to 20 years after diagnosis. We also define a subgroup of triple-negative breast cancers in which cancer rarely recurs after five years, and a separate subgroup in which patients remain at risk. Use of the integrative subtypes improves the prediction of late, distant relapse beyond what is possible with clinical covariates (nodal status, tumour size, tumour grade and immunohistochemical subtype). These findings highlight opportunities for improved patient stratification and biomarker-driven clinical trials. A statistical framework for breast-cancer recurrence uses long-term follow-up data and a knowledge of molecular subcategories to model distinct disease stages and to predict the risk of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Simultaneous Inference in General Parametric Models
Hothorn, T., Bretz, F., & Westfall, P. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,847
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationA Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,094
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
On the regression analysis of multivariate failure time data
PRENTICE, R. L., WILLIAMS, B. J., & PETERSON, A. V. (1981) · Biometrika · doi:10.1093/biomet/68.2.373 · Cited by 1,333
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000279 · Cited by 1,116
Self-citationDesmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis
Clarke, C., Madden, S. F., Doolan, P., Aherne, S. T., Joyce, H., O’Driscoll, L., Gallagher, W. M., Hennessy, B. T., Moriarty, M., Crown, J., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt208 · Cited by 849
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
Survival and Event History Analysis
Aalen, O. O., Borgan, Ø., & Gjessing, H. K. (2008) · Statistics for Biology and Health · doi:10.1007/978-0-387-68560-1 · Cited by 813
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Significance of ipsilateral breast tumour recurrence after lumpectomy
Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., Mamounas, E. P., Deutsch, M., & Margolese, R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90475-5 · Cited by 556
mstate: An R Package for the Analysis of Competing Risks and Multi-State Models
Wreede, L. C. D., Fiocco, M., & Putter, H. (2011) · Journal of Statistical Software · doi:10.18637/jss.v038.i07 · Cited by 478
survcomp: an R/Bioconductor package for performance assessment and comparison of survival models
Schröder, M. S., Culhane, A. C., Quackenbush, J., & Haibe-Kains, B. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr511 · Cited by 470
Wishart, G. C., Azzato, E. M., Greenberg, D. C., Rashbass, J., Kearins, O., Lawrence, G., Caldas, C., & Pharoah, P. D. (2010) · Breast Cancer Research · doi:10.1186/bcr2464 · Cited by 418
Self-citationSgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Gendoo, D. M. A., Ratanasirigulchai, N., Schröder, M. S., Paré, L., Parker, J. S., Prat, A., & Haibe-Kains, B. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv693 · Cited by 394
Loi, S., Haibe-Kains, B., Desmedt, C., Wirapati, P., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Ryder, K., Reid, J. F., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-239 · Cited by 389
Clark, G. M., Sledge, G. W., Osborne, C. K., & McGuire, W. L. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.55 · Cited by 374
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J. D., et al. (2010) · Nature Medicine · doi:10.1038/nm.2090 · Cited by 352
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer
Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023033708204 · Cited by 270
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1164 · Cited by 270
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. H. (2014) · Genome biology · doi:10.1186/preaccept-1094756427137059 · Cited by 225
Self-citationFactors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
Sestak, I., Dowsett, M., Zabaglo, L., Lopez-Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt244 · Cited by 222
A simple stochastic model of recovery, relapse, death and loss of patients.
Fix, E., & Neyman, J. (1951) · PubMed · Cited by 219
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Nagalla, S., Chou, J. W., Willingham, M. C., Ruiz, J., Vaughn, J. P., Dubey, P., Lash, T. L., Hamilton-Dutoit, S. J., Bergh, J., Sotiriou, C., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r34 · Cited by 196
Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thürlimann, B., Colleoni, M., & Cuzick, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4258 · Cited by 193
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling
Shrestha, Y., Schafer, E. J., Boehm, J. S., Thomas, S. R., He, F., Du, J., Wang, S., Barretina, J., Weir, B. A., Zhao, J. J., et al. (2012) · Oncogene · doi:10.1038/onc.2011.515 · Cited by 165
Holland, D. G., Burleigh, A., Git, A., Goldgraben, M. A., Pérez-Mancera, P. A., Chin, S., Hurtado, A., Bruna, A., Ali, H. R., Greenwood, W., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100122 · Cited by 145
Self-citationEstimation and Prediction in a Multi-State Model for Breast Cancer
Putter, H., van der Hage, J. A., de Bock, G. H., Galta, R. E., & van de Velde, C. J. �. (2006) · Biometrical Journal · doi:10.1002/bimj.200510218 · Cited by 123
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
Richman, J., & Dowsett, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0145-5 · Cited by 110
Klein, J. P., Keiding, N., & Copelan, E. A. (1993) · Statistics in Medicine · doi:10.1002/sim.4780122408 · Cited by 103
Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers
Sanchez-Garcia, F., Villagrasa, P., Matsui, J., Kotliar, D., Castro, V., Akavia, U.-D., Chen, B.-J., Saucedo-Cuevas, L. P., Barrueco, R. R., Llobet‐Navàs, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.048 · Cited by 101
Reduced‐rank proportional hazards regression and simulation‐based prediction for multi‐state models
Fiocco, M. F., Putter, H., & van Houwelingen, H. C. (2008) · Statistics in Medicine · doi:10.1002/sim.3305 · Cited by 70
Improved web-based calculators for predicting breast carcinoma outcomes
Michaelson, J. S., Chen, L. L., Bush, D. M., Fong, A., Smith, B. L., & Younger, J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1366-9 · Cited by 65
Meier‐Hirmer, C., & Schumacher, M. C. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-80 · Cited by 45
Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia
Liu, H., Feng, X., Ennis, K. N., Behrmann, C. A., Sarma, P. N., Jiang, T. T., Kofuji, S., Niu, L., Stratton, Y., Thomas, H. E., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.022 · Cited by 29
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“org and clinical data are available as Supplementary Table S1 in Rueda and colleagues’ study (36).”
MethodDeciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Nguyen, B., Fong, C., Luthra, A., Smith, S. A., DiNatale, R. G., Nandakumar, S., Walch, H., Chatila, W. K., Madupuri, R., Kundra, R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.003 · Cited by 623
Wang, R., Zhu, Y., Liu, X., Liao, X., He, J., & Niu, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-6311-z · Cited by 459
Metadata
- Authors
- Rueda, O. M., Sammut, S.-J., Seoane, J. A., Chin, S.-F., Caswell-Jin, J. L., Callari, M., Batra, R., Pereira, B., Bruna, A., Ali, H. R., Provenzano, E., Liu, B., Parisien, M., Gillett, C., McKinney, S., Green, A. R., Murphy, L., Purushotham, A., Ellis, I. O., Pharoah, P. D., Rueda, C., Aparicio, S., Caldas, C., & Curtis, C.
- Venue
- Nature
- Published
- 2019-03
- Volume
- 567
- Issue
- 7748
- Pages
- 399-404
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2920863604
- Cited by
- 417
- References
- 52
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.